Coadministration has not been studied. The coadministration of maraviroc dosed at 300 mg twice daily would be possible from a pharmacokinetic standpoint. Maraviroc is metabolized by CYP3A4. Lenacapavir is mainly cleared as unchanged drug and is a moderate inhibitor of CYP3A4, however, no a priori dose adjustment of maraviroc is needed in the absence of boosted antiretroviral agents.